Actinogen Medical LimitedASX: ACW

ACW XanaMIA Alzheimers trial results

· Issued by Actinogen Medical Limited via ASX

Filed with ASX · · 19 pages · English

Summary by 6ix AI

Actinogen Medical Limited has announced the topline results from its pivotal XanaMIA trial, which evaluated the efficacy of Xanamem in treating Alzheimer's disease in older patients. Xanamem was found to be safe and well tolerated over the treatment period, with a favorable longer-term safety profile. The company plans to continue the Open Label Extension phase of the trial to gather additional data on disease stabilization.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

ASX ANNOUNCEMENT Actinogen pivotal Alzheimer’s disease trial demonstrates trends toward clinical benefit in older patients and favourable longer term safety profile Sydney, 19 November 2026. Actinogen Medical ASX: ACW (“ACW” or “the Company”) today announces ® topline results from its...

Actinogen Medical Limited on 6ix

In the deck

Story so far

Earlier from Actinogen Medical

Later from Actinogen Medical

All Actinogen Medical news releases